Compare TXMD & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TXMD | EVAX |
|---|---|---|
| Founded | 2008 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.9M | 27.4M |
| IPO Year | 2012 | 2020 |
| Metric | TXMD | EVAX |
|---|---|---|
| Price | $2.23 | $3.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.33 |
| AVG Volume (30 Days) | ★ 33.0K | 32.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.61 | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $1,761,000.00 | N/A |
| Revenue This Year | $427.09 | $129.07 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $90.64 | ★ N/A |
| Revenue Growth | ★ 35.25 | N/A |
| 52 Week Low | $0.72 | $1.20 |
| 52 Week High | $2.95 | $12.15 |
| Indicator | TXMD | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 49.23 | 39.29 |
| Support Level | $1.05 | $2.56 |
| Resistance Level | $2.54 | $3.54 |
| Average True Range (ATR) | 0.13 | 0.22 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 40.91 | 25.62 |
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.